Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
Phase 1
168
about 5.5 years
18+
11 sites in CA, CO, IN +7
About this study
This trial is testing a treatment called TJ033721 (givastomig) in people with advanced or metastatic solid tumors. The goal is to see if it's safe and how well it works, along with its effects on the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take TJ033721 (givastomig)
- 2.Take TJ033721 (givastomig) , nivolumab, chemotherapy
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
durvalumab, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion
Primary: Dose-limiting toxicities (DLTs), Incidence and severity of AEs, Maximum tolerated or administered dose (MTD, MAD)
Secondary: Pharmacokinetic (PK) Parameters: AUCt, Pharmacokinetic (PK) Parameters: AUC∞, Pharmacokinetic (PK) Parameters: Cmax, Pharmacokinetic Parameters: T1/2, Pharmacokinetic Parameters: Tmax
Oncology